Form D · Biotechnology
ChromaDex Corp.
Los Angeles, CA · CIK 0001386570
Offering snapshot reported Oct 14, 2022 · SEC filing
- Reported sold
- $3.1M Offering amount: $3.1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2022 | Initial | $3,100,000 | No comparison | 3 | SEC filing |
| Mar 3, 2021 | Initial | $24,999,995 | No comparison | 1 | SEC filing |
| May 20, 2020 | Initial | $5,000,000 | No comparison | 2 | SEC filing |
| Aug 29, 2019 | Initial | $7,000,000 | No comparison | 3 | SEC filing |
| May 24, 2019 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Nov 29, 2017 | Initial | $22,999,996 | No comparison | 10 | SEC filing |
| Aug 31, 2017 | Initial | $5,110,084 | No comparison | 2 | SEC filing |
| Jun 6, 2017 | Initial | $16,389,916 | No comparison | 2 | SEC filing |
| May 5, 2017 | Initial | $3,500,000 | No comparison | 2 | SEC filing |
| Mar 22, 2017 | Initial | $1,000,003 | No comparison | 3 | SEC filing |
| Mar 16, 2016 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Oct 14, 2014 | Initial | $445,000 | No comparison | 1 | SEC filing |
| Oct 24, 2013 | Initial | $3,000,000 | No comparison | 2 | SEC filing |
| Feb 22, 2012 | Initial | $3,699,998 | No comparison | 12 | SEC filing |
| May 27, 2010 | Initial | $3,674,998 | No comparison | 45 | SEC filing |
| Aug 4, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 30, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 7, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-461811
Source: Form D, filed Oct 14, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen L. Allen | Director |
| Steve L. Allen | Director |
| Jeff L. Baxter | Director |
| Stephen L. Block | Director |
| Steven A. Block | Director |
| Lisa Bratkovich | Executive |
| Michael Brauser | Director |
| Ann N. Cohen | Director |
| Reid Dabney | Director |
| Hugh Dunkerley | Director |
| Hugh Dunkerly | Director |
| Kevin M. Farr | Executive |
| Rob Fried | Director |
| Robert N. Fried | Director, Executive |
| Mark L. Friedman | Executive |
| Brianna N. Gerber | Executive |
| Mark S. Germain | Director |
| Mark Germaine | Director |
| Kurt L. Gustafson | Director |
| Glenn L. Halpryn | Director |
| Jeffrey Himmel | Director, Executive |
| Barry Honig | Director |
| Frank L. Jr. Jaksch | Director |
| Frank, Jr. Jaksch | Director, Executive |
| Frank L. Jaksch, Jr. | Director, Executive |
| Megan Jordan | Executive |
| Tony L. Lau | Director |
| Tsz Ho Tony L. Lau | Director |
| Curtis Lockshin | Director |
| Gary N. Ng | Director |
| Kristin N. Patrick | Director |
| Troy L. Rhonemus | Executive |
| Matthew Roberts | Executive |
| Steven N. Rubin | Director |
| Hamed N. Shahbazi | Director |
| Troy Thonemus | Executive |
| Tom Varvaro | Executive |
| Thomas L. Varvaro | Executive |
| Wing Tak Wendy L. Yu | Director |
| Wendy N. Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10900 Wilshire Blvd Suite 600
Los Angeles, CA, 90024
Los Angeles, CA, 90024